Partner with Experts in Immunogenicity Strategy.
Introducing Trusted Expert Advice (TEA), a personalized consulting service designed to support growing biotech companies navigating the complex world of immunogenicity risk strategy.
Through one-on-one consultations, TEA offers a collaborative partnership that leverages decades of experience in pre-clinical and clinical immunogenicity risk strategies. Our seasoned consultants possess a profound understanding of regulatory agency requirements and are able to provide tailored recommendations and assistance to enhance your biologic therapeutic pipeline and mitigate clinical failure risks.
Partner with EpiVax to confidently advance your biotech innovations and achieve your next milestones with expert guidance.
TEA consultants deliver insights to give your pipeline
a competitive edge at every step of the preclinical development journey:
Support strategic planning and fundraising: Reliable immunogenicity data bolsters grant applications, publications, investor materials, and internal product characterization discussions.
Meet Vibha Jawa, Ph.D., FAAPS
Cheif Scientific Officer, EpiVax
Dr. Jawa brings over 25 years of experience advancing biologics, gene therapies and vaccines. As a globally recognized expert in translational medicine and immunogenicity strategy, she has supported over 20 successful IND, BLA, and MAA filings across a wide range of therapeutic modalities.
Prior to joining EpiVax as Chief Scientific Officer, Dr. Jawa held senior leadership positions at Bristol Myers Squibb, Merck, and Amgen, where she led cross-functional teams in DMPK, bioanalysis, and immunogenicity assessment from discovery through clinical development. Earlier in her career, she contributed to the development of the first approved gene therapy product as part of the team at the Institute of Gene Therapy. She is an extensively published thought leader with more than 100 peer-reviewed publications and holds leadership roles in prominent scientific organizations, including AAPS, IQ, and EIP.
Dr. Jawa’s areas of specialization include:
Immunogenicity risk assessment and strategic implementation of clinical immunogenicity monitoring across therapeutic modalities
Bioanalytical strategy and assay development for PK, PD, biomarkers, and immunogenicity
DMPK and clinical pharmacology support across early and late-stage development
Reverse translation of clinical data to improve early development decisions
Protein engineering and developability assessment, including potency, safety, and expression
CMC and Manufacturing related critical quality attribute related assessments and setting clinically relevant thresholds and specifications
Regulatory strategy and engagement with global agencies (FDA, EMA, PMDA, and others)
Authoring and reviewing IND-enabling documents, clinical protocols, and regulatory submissions
Development support for antibodies, bispecifics, peptides, nanobodies, cell/gene therapies, and vaccines
Through TEA consulting, Dr. Jawa offers biotech innovators more than just guidance; she brings a strategic perspective shaped by decades of therapeutic development experience. One-on-one discussions with her will allow teams to design smarter preclinical programs, translate in silico and in vitro data into confident decisions, and approach regulatory interactions with clarity.
Whether you’re preparing your first IND application or navigating the challenges of a complex modality, Dr. Jawa’s insights will support better planning, stronger submissions, and more informed development decisions.